Patents by Inventor Kim Pettersson
Kim Pettersson has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11921115Abstract: Aspects of the disclosure relate to improved methods for predicting whether a prostate tissue biopsy obtained from a subject will contain detectable prostate cancer. In some embodiments, the disclosure provides improved prostate antigen standards for quantifying levels of prostate antigens.Type: GrantFiled: March 25, 2016Date of Patent: March 5, 2024Assignee: OPKO Diagnostics, LLCInventors: Vincent Linder, Christina Higgins, Kim Pettersson
-
Publication number: 20230393137Abstract: Aspects of the disclosure relate to improved methods for predicting whether a prostate tissue biopsy obtained from a subject will contain detectable prostate cancer.Type: ApplicationFiled: May 30, 2023Publication date: December 7, 2023Applicant: OPKO Diagnostics, LLCInventors: Vincent Linder, David Steinmiller, Kim Pettersson, Timo Lovgren, Hans Lilja, Andrew J. Vickers, Peter T. Scardino
-
Patent number: 11761962Abstract: Aspects of the disclosure relate to improved methods for predicting whether a prostate tissue biopsy obtained from a subject will contain detectable prostate cancer.Type: GrantFiled: March 27, 2015Date of Patent: September 19, 2023Assignee: OPKO Diagnostics, LLCInventors: Vincent Linder, David Steinmiller, Kim Pettersson, Timo Lovgren, Hans Lilja, Andrew J. Vickers, Peter T. Scardino
-
Publication number: 20210278411Abstract: The present disclosure relates to non-invasive diagnostics of cancers, such as breast cancer, colorectal cancer, pancreatic cancer and prostate cancer, on the basis of altered glycosylation patterns of cancer-associated biomarkers.Type: ApplicationFiled: July 14, 2017Publication date: September 9, 2021Applicant: Kaivogen OyInventors: Kamlesh GIDWANI, Kim PETTERSSON, Henna KEKKI
-
Publication number: 20200284795Abstract: The present disclosure relates to methods and a kit for diagnosing, prognosing and/or monitoring a gynaecological disease, especially epithelial ovarian cancer, on the basis of altered glycosylation pattern of CA125. More specifically, said altered glycosylation pattern relates to that recognizable by MGL.Type: ApplicationFiled: May 1, 2020Publication date: September 10, 2020Applicant: KAIVOGEN OYInventors: Kim PETTERSSON, Kamlesh GIDWANI
-
Patent number: 10684285Abstract: The present disclosure relates to methods and a kit for diagnosing, prognosing and/or monitoring a gynaecological disease, especially epithelial ovarian cancer, on the basis of altered glycosylation pattern of CA125. More specifically, said altered glycosylation pattern relates to that recognizable by MGL.Type: GrantFiled: July 4, 2016Date of Patent: June 16, 2020Assignee: KAIVOGEN OYInventors: Kim Pettersson, Kamlesh Gidwani
-
Publication number: 20180156806Abstract: The present disclosure relates to methods and a kit for diagnosing, prognosing and/or monitoring a gynaecological disease, especially epithelial ovarian cancer, on the basis of altered glycosylation pattern of CA125. More specifically, said altered glycosylation pattern relates to that recognizable by MGL.Type: ApplicationFiled: July 4, 2016Publication date: June 7, 2018Applicant: TURUN YLIOPISTOInventors: Kim PETTERSSON, Kamlesh GIDWANI
-
Publication number: 20160025732Abstract: Aspects of the disclosure relate to improved methods for predicting whether a prostate tissue biopsy obtained from a subject will contain detectable prostate cancer.Type: ApplicationFiled: March 27, 2015Publication date: January 28, 2016Applicant: OPKO Diagnostics, LLCInventors: Vincent Linder, David Steinmiller, Kim Pettersson, Timo Lovgren, Hans Lilja, Andrew J. Vickers, Peter T. Scardino
-
Patent number: 8669120Abstract: A high capacity solid phase for bioaffinity assays and other solid phase applications prepared by coating a solid support with an analyte-specific biomolecule in the presence of a zwitterionic additive is described. Structures prepared according to the invention provide high capacity solid phases with enhanced binding properties, which are advantageous for any solid phase based assay.Type: GrantFiled: July 15, 2009Date of Patent: March 11, 2014Assignee: Innotrac Diagnostics OyInventors: Johanna Ylikotila, Lasse Välimaa, Harri Takalo, Kim Pettersson
-
Publication number: 20120264139Abstract: This invention concerns a bioaffinity assay for quantitative determination in a sample of free PAPP-A, defined as the pregnancy associated plasma protein A (PAPP-A) that is not complexed to the proform of major basic protein (proMBP), wherein free PAPP-A is determined either i) as a calculated difference between measured total PAPP-A and measured PAPP-A complexed to proMBP, or ii) by a direct bioaffinity assay measuring only free PAPP-A. Furthermore, the invention concerns a method for diagnosing an acute coronary syndrome in a person by using as marker either free PAPP-A as such or a ratio free PAPP-A/total PAPP-A, free PAPP-A/PAPP-A complexed to proMBP, or PAPP-A complexed to proMBP/total PAPP-A.Type: ApplicationFiled: June 28, 2012Publication date: October 18, 2012Inventors: Qiu-Ping Qin, Kim Pettersson
-
Publication number: 20110177620Abstract: A nanoparticle having a detectible feature and whose diameter is less than 200 nm, and which is coated with multiple specific binding reactants such that the affinity constant of the nanoparticle towards an analyte exceeds that of free binding reactant towards the analyte and/or the association rate constant between the nanoparticle and the analyte exceeds the association rate constant between the free binding reactant and the analyte. Also disclosed is a homogenous assay based on a first group labeled with a luminescent energy donor nanoparticle and a second group labeled with an energy acceptor compound, where the donor has a long excited state lifetime, and the increase or decrease, respectively, in the energy transfer from the donor to the acceptor resulting from shortening or lengthening, respectively, of the distance between these groups, is measured.Type: ApplicationFiled: March 31, 2011Publication date: July 21, 2011Inventor: Kim PETTERSSON
-
Patent number: 7872104Abstract: This invention concerns an antibody which binds with high affinity to human single-chain intact, i.e. not internally cleaved, mature and/or zymogen forms of prostate specific antigen (SCINT PSA). The antibody does not bind to a nicked PSA (PSA-N), wherein said PSA-N has been formed by internal peptide bond cleavage(s) of SCINT PSA resulting in two-chain or multi-chain PSA. This invention further concerns an immunoassay and a method for differentiating patients with cancer of the prostate (PCa) from patients with benign prostatic hyperplasia (BPH) and/or healthy male subjects without PCa, patients with aggressive PCa from patients with indolent PCa and/or patients with clinically localized and/or organ confined PCa from patients with extraprostatic extension of PCa and/or PCa with metastatic spread to lymph nodes or bone marrow using said antibody.Type: GrantFiled: September 26, 2001Date of Patent: January 18, 2011Assignee: Arctic Partners Oy ABInventors: Kim Pettersson, Hans Lilja, Timo Lövgren, Pauliina Niemelä
-
Patent number: 7824876Abstract: A bioaffinity assay for quantitative determination in a sample of free PAPP-A, defined as the pregnancy associated plasma protein A (PAPP-A) that is not complexed to the proform of major basic protein (proMBP), where free PAPP-A is determined either i) as a calculated difference between measured total PAPP-A and measured PAPP-A complexed to proMBP, or ii) by a direct bioaffinity assay measuring only free PAPP-A. Also disclosed is a method for diagnosing an acute coronary syndrome in a person by using as marker either free PAPP-A as such or a ratio free PAPP-A/total PAPP-A, free PAPP-A/PAPP-A complexed to proMBP, or PAPP-A complexed to proMBP/total PAPP-A.Type: GrantFiled: January 19, 2005Date of Patent: November 2, 2010Assignee: Turun YliopistoInventors: Qiu-Ping Qin, Kim Pettersson
-
Publication number: 20100240115Abstract: A nanoparticle having a detectable feature and whose diameter is less than 200 nm, and which is coated with multiple specific binding reactants such that the affinity constant of the nanoparticle towards an analyte exceeds that of free binding reactant towards the analyte and/or the association rate constant between the nanoparticle and the analyte exceeds the association rate constant between the free binding reactant and the analyte. Also disclosed is a homogenous assay based on a first group labeled with a luminescent energy donor nanoparticle and a second group labeled with an energy acceptor compound, where the donor has a long excited state lifetime, and the increase or decrease, respectively, in the energy transfer from the donor to the acceptor resulting from shortening or lengthening, respectively, of the distance between these groups, is measured.Type: ApplicationFiled: December 11, 2009Publication date: September 23, 2010Inventor: Kim PETTERSSON
-
Publication number: 20100173425Abstract: A high capacity solid phase for bioaffinity assays and other solid phase applications prepared by coating a solid support with an analyte-specific biomolecule in the presence of a zwitterionic additive is described. Structures prepared according to the invention provide high capacity solid phases with enhanced binding properties, which are advantageous for any solid phase based assay.Type: ApplicationFiled: July 15, 2009Publication date: July 8, 2010Applicant: Innotrac Diagnostics OvInventors: Johanna Ylikotila, Lasse Välimaa, Harri Takalo, Kim Pettersson
-
Patent number: 7638292Abstract: A method for detection and/or quantification of cardiac troponin I (cTnI) in a sample derived from an individual's blood, the method being based on a sandwich immunoassay employing at least two capture antibodies and at least one tracer antibody, in which a first capture antibody is directed to the N-terminal part of cTnI, to the C-terminal part of cTnI or to the part of the cTnI midfragment, which is slightly affected by the interfering factor, and a second capture antibody is directed to another of these parts, and a tracer antibody is directed to the N-terminal part of cTnI, to the C-terminal part of cTnI or to TnC, which is complexed with cTnI.Type: GrantFiled: November 13, 2007Date of Patent: December 29, 2009Assignee: University of TurkuInventors: Susann Eriksson, Kim Pettersson
-
Publication number: 20090263914Abstract: A nanoparticle having a detectible feature and whose diameter is less than 200 nm, and which is coated with multiple specific binding reactants such that the affinity constant of the nanoparticle towards an analyte exceeds that of free binding reactant towards the analyte and/or the association rate constant between the nanoparticle and the analyte exceeds the association rate constant between the free binding reactant and the analyte. Also disclosed is a homogenous assay based on a first group labeled with a luminescent energy donor nanoparticle and a second group labeled with an energy acceptor compound, where the donor has a long excited state lifetime, and the increase or decrease, respectively, in the energy transfer from the donor to the acceptor resulting from shortening or lengthening, respectively, of the distance between these groups, is measured.Type: ApplicationFiled: February 3, 2009Publication date: October 22, 2009Inventor: Kim PETTERSSON
-
Publication number: 20080153109Abstract: A method for detection and/or quantification of cardiac troponin I (cTnI) in a sample derived from an individual's blood, the method being based on a sandwich immunoassay employing at least two capture antibodies and at least one tracer antibody, in which a first capture antibody is directed to the N-terminal part of cTnI, to the C-terminal part of cTnI or to the part of the cTnI midfragment, which is slightly affected by the interfering factor, and a second capture antibody is directed to another of these parts, and a tracer antibody is directed to the N-terminal part of cTnI, to the C-terminal part of cTnI or to TnC, which is complexed with cTnI.Type: ApplicationFiled: November 13, 2007Publication date: June 26, 2008Inventors: Susann Eriksson, Kim Pettersson
-
Patent number: 7348157Abstract: A method for detection and/or quantification of cardiac troponin I (cTnI) in a sample derived from an individual's blood, the method being based on a sandwich immunoassay employing at least two capture antibodies and at least one tracer antibody, in which a first capture antibody is directed to the N-terminal part of cTnI, to the C-terminal part of cTnI or to the part of the cTnI midfragment, which is slightly affected by the interfering factor, and a second capture antibody is directed to another of these parts, and a tracer antibody is directed to the N-terminal part of cTnI, to the C-terminal part of cTnI or to TnC, which is complexed with cTnI.Type: GrantFiled: April 7, 2004Date of Patent: March 25, 2008Assignee: University of TurkuInventors: Susann Eriksson, Kim Pettersson
-
Patent number: 7285418Abstract: The invention provides a method for assaying for troponin I in a sample such as serum, the method comprising a determination of the troponin I concentration in a sample using a standard preparation that comprises a complete native troponin complex. One exemplary assay for troponin I concentration according to the invention is an immunoassay. Further contemplated in the method is a step comprising contacting the sample with a Ca2+-binding agent. Another aspect of the invention is the standard preparation comprising a complete native troponin complex. Yet another aspect of the invention is a kit for use in the assay method comprising the standard preparation, a detectable label, and a troponin I binding partner, such as an anti-troponin I antibody. All aspects of the invention are usefully practiced using human materials, such as a human troponin complex, and/or human sources for samples.Type: GrantFiled: July 1, 2002Date of Patent: October 23, 2007Assignee: Hytest Ltd.Inventors: Alex G. Katrukha, Sergei Severin, Anastasia Bersenikova, Tatiana Esakova, Kim Pettersson